{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:48:30Z","timestamp":1776721710223,"version":"3.51.2"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["92159302"],"award-info":[{"award-number":["92159302"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82473213"],"award-info":[{"award-number":["82473213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82470099"],"award-info":[{"award-number":["82470099"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-026-03141-w","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:16:37Z","timestamp":1773299797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of neoadjuvant targeted therapy in non-small cell lung cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"15","author":[{"given":"Honglin","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weimin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panwen","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"3","key":"3141_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"3141_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"3141_CR3","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, et al. The 2015 world health organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2015;10(9):1243\u201360. https:\/\/doi.org\/10.1097\/JTO.0000000000000630.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"issue":"3","key":"3141_CR4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1136\/thx.2007.094912","volume":"64","author":"JJ Hung","year":"2009","unstructured":"Hung JJ, Hsu WH, Hsieh CC, et al. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax. 2009;64(3):192\u20136. https:\/\/doi.org\/10.1136\/thx.2007.094912.","journal-title":"Thorax"},{"key":"3141_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.xjon.2022.03.004","volume":"10","author":"T Takenaka","year":"2022","unstructured":"Takenaka T, Yano T, Yamazaki K, et al. Survival after recurrence following surgical resected non-small cell lung cancer: a multicenter, prospective cohort study. JTCVS Open. 2022;10:370\u201381. https:\/\/doi.org\/10.1016\/j.xjon.2022.03.004.","journal-title":"JTCVS Open"},{"issue":"10","key":"3141_CR6","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jtho.2024.06.010","volume":"19","author":"JD Spicer","year":"2024","unstructured":"Spicer JD, Cascone T, Wynes MW, et al. Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the International Association for the Study of Lung Cancer. J Thorac Oncol. 2024;19(10):1373\u2013414. https:\/\/doi.org\/10.1016\/j.jtho.2024.06.010.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"3141_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105759","volume":"10","author":"G Rossi","year":"2025","unstructured":"Rossi G, Barcellini L, Tagliamento M, et al. Immunotherapy for resectable NSCLC: neoadjuvant\/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses. ESMO Open. 2025;10(9):105759. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105759.","journal-title":"ESMO Open"},{"key":"3141_CR8","doi-asserted-by":"publisher","unstructured":"E A, Bj S, R H, N P, K O, Bgm H. Neoadjuvant immunotherapy for non-small cell lung cancer: Right drugs, right patient, right time? J Immunother Cancer. 2021;9(6). https:\/\/doi.org\/10.1136\/jitc-2020-002248","DOI":"10.1136\/jitc-2020-002248"},{"issue":"12","key":"3141_CR9","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1093\/annonc\/mdm201","volume":"18","author":"M Kaufmann","year":"2007","unstructured":"Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18(12):1927\u201334. https:\/\/doi.org\/10.1093\/annonc\/mdm201.","journal-title":"Ann Oncol"},{"issue":"21","key":"3141_CR10","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2202170.","journal-title":"N Engl J Med"},{"issue":"6","key":"3141_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer. N Engl J Med. 2023;389(6):491\u2013503. https:\/\/doi.org\/10.1056\/NEJMoa2302983.","journal-title":"N Engl J Med"},{"issue":"9","key":"3141_CR12","doi-asserted-by":"publisher","first-page":"354","DOI":"10.6004\/jnccn.2025.0043","volume":"23","author":"GJ Riely","year":"2025","unstructured":"Riely GJ, Wood DE, Aisner DL, et al. NCCN guidelines\u00ae insights: non-small cell lung cancer, version 7.2025. J Natl Compr Canc Netw. 2025;23(9):354\u201362. https:\/\/doi.org\/10.6004\/jnccn.2025.0043.","journal-title":"J Natl Compr Canc Netw"},{"key":"3141_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.003","author":"A Zer","year":"2025","unstructured":"Zer A, Ahn MJ, Barlesi F, et al. Early and locally advanced non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.003.","journal-title":"Ann Oncol"},{"issue":"43","key":"3141_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aav3937","volume":"5","author":"E Sugiyama","year":"2020","unstructured":"Sugiyama E, Togashi Y, Takeuchi Y, et al. Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. Sci Immunol. 2020;5(43):eaav3937. https:\/\/doi.org\/10.1126\/sciimmunol.aav3937.","journal-title":"Sci Immunol"},{"key":"3141_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bioactmat.2025.03.003","volume":"49","author":"N Chen","year":"2025","unstructured":"Chen N, Li Z, Liu H, et al. Enhancing PD-1 blockade in NSCLC: reprogramming tumor immune microenvironment with albumin-bound statins targeting lipid rafts and mitochondrial respiration. Bioact Mater. 2025;49:140\u201353. https:\/\/doi.org\/10.1016\/j.bioactmat.2025.03.003.","journal-title":"Bioact Mater"},{"issue":"8","key":"3141_CR16","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1158\/1078-0432.CCR-19-2027","volume":"26","author":"K Isomoto","year":"2020","unstructured":"Isomoto K, Haratani K, Hayashi H, et al. Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer. Clin Cancer Res. 2020;26(8):2037\u201346. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2027.","journal-title":"Clin Cancer Res"},{"key":"3141_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1036334","volume":"13","author":"W Liu","year":"2022","unstructured":"Liu W, Ren S, Xiao Y, Yang L, Zeng C, Hu Y. Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: current status and future considerations. Front Pharmacol. 2022;13:1036334. https:\/\/doi.org\/10.3389\/fphar.2022.1036334.","journal-title":"Front Pharmacol"},{"issue":"11","key":"3141_CR18","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","volume":"188","author":"Z Liu","year":"2025","unstructured":"Liu Z, Yang Z, Wu J, et al. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell. 2025;188(11):3081-3096.e19. https:\/\/doi.org\/10.1016\/j.cell.2025.03.018.","journal-title":"Cell"},{"issue":"2","key":"3141_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127\u201337. https:\/\/doi.org\/10.1038\/35052073.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3141_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. https:\/\/doi.org\/10.1136\/bmj.b2700.","journal-title":"BMJ"},{"issue":"3","key":"3141_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst. 2000;92(3):205\u201316. https:\/\/doi.org\/10.1093\/jnci\/92.3.205.","journal-title":"J Natl Cancer Inst"},{"key":"3141_CR22","unstructured":"Recist 1.1 \u2013 recist. https:\/\/recist.eortc.org\/recist-1-1-2\/. Accessed 5 Feb 2026."},{"key":"3141_CR23","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Bethesda (MD):U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2009. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf."},{"key":"3141_CR24","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Bethesda (MD):U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2017.https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"3141_CR25","doi-asserted-by":"publisher","unstructured":"Porritt K, McArthur A, Lockwood C. JBI Manual for Evidence Implementation. In: Munn Z, editor. JBI; 2020. https:\/\/doi.org\/10.46658\/JBIMEI-20-01.","DOI":"10.46658\/JBIMEI-20-01"},{"key":"3141_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100715","author":"BC Ahn","year":"2022","unstructured":"Ahn BC, Park C, Kim MS, et al. OP27 A phase II study of neoadjuvant erlotinib for operable stage II or IIIA non-small cell lung cancer with epidermal growth factor receptor activating mutations. ESMO Open. 2022. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100715.","journal-title":"ESMO Open"},{"issue":"12","key":"3141_CR27","doi-asserted-by":"publisher","first-page":"S394","DOI":"10.1097\/JTO.0b013e31820108f5","volume":"5","author":"T Lim","year":"2010","unstructured":"Lim T, Baek KK, Yi JH, et al. A phase II trial of neoadjuvant erlotinib (TARCEVA\u00ae) followed by surgery for selected patients with stage IIIA, N2-positive non-small cell lung cancer. J Thorac Oncol. 2010;5(12):S394. https:\/\/doi.org\/10.1097\/JTO.0b013e31820108f5.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"3141_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3760\/cma.j.issn.0253-3766.2018.02.010","volume":"40","author":"WQ Chen","year":"2018","unstructured":"Chen WQ, Li P, Wang Q, et al. A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage \u2162A EGFR-mutant lung adenocarcinoma. Zhonghua Zhong Liu Za Zhi. 2018;40(2):133\u20137. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-3766.2018.02.010.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"3141_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1194100","author":"Y Qi","year":"2023","unstructured":"Qi Y, Gu L, Shen J, et al. An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1194100.","journal-title":"Front Oncol"},{"key":"3141_CR30","doi-asserted-by":"publisher","first-page":"viii738","DOI":"10.1093\/annonc\/mdy424.058","volume":"29","author":"WZ Zhong","year":"2018","unstructured":"Zhong WZ, Wu YL, Chen KN, et al. CTONG 1103: erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non-small cell lung cancer (EMERGING): a randomised study. Ann Oncol. 2018;29:viii738. https:\/\/doi.org\/10.1093\/annonc\/mdy424.058.","journal-title":"Ann Oncol"},{"key":"3141_CR31","doi-asserted-by":"publisher","first-page":"i24","DOI":"10.1093\/annonc\/mdv049.01","volume":"26","author":"B Han","year":"2015","unstructured":"Han B, Xiong L, Sun J, et al. Erlotinib as neoadjuvant treatment in endobronchial ultrasound confirmed stage IIIA-N2 non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation (EXON 19 OR 21) (NCT01217619, ESTERN): a prospective, single arm, phase ii clinical trial. Ann Oncol. 2015;26:i24. https:\/\/doi.org\/10.1093\/annonc\/mdv049.01.","journal-title":"Ann Oncol"},{"issue":"3","key":"3141_CR32","doi-asserted-by":"publisher","first-page":"S188","DOI":"10.1016\/j.jtho.2021.01.072","volume":"16","author":"A Piper-Vallillo","year":"2021","unstructured":"Piper-Vallillo A, Mak R, Lanuti M, et al. FP01.05 the ASCENT trial: a phase II study of neoadjuvant\/adjuvant afatinib, chemoradiation +\/- surgery for stage III EGFR-mutant NSCLC. J Thorac Oncol. 2021;16(3):S188. https:\/\/doi.org\/10.1016\/j.jtho.2021.01.072.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"3141_CR33","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jtcvs.2020.02.131","volume":"161","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Fu F, Hu H, et al. Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non\u2013small cell lung cancer: a phase II study. J Thorac Cardiovasc Surg. 2021;161(2):434-442.e2. https:\/\/doi.org\/10.1016\/j.jtcvs.2020.02.131.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"11","key":"3141_CR34","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.1016\/j.jtho.2023.09.196","volume":"18","author":"JB Lee","year":"2023","unstructured":"Lee JB, Choi SJ, Park YJ, et al. MA11.11 drug tolerant persister cells to neoadjuvant osimertinib in resectable non-small cell lung cancer harboring EGFR mutations (NORA). J Thorac Oncol. 2023;18(11):S140\u20131. https:\/\/doi.org\/10.1016\/j.jtho.2023.09.196.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"3141_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40349-z","volume":"14","author":"D Bian","year":"2023","unstructured":"Bian D, Sun L, Hu J, et al. Neoadjuvant afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study. Nat Commun. 2023;14(1):4655. https:\/\/doi.org\/10.1038\/s41467-023-40349-z.","journal-title":"Nat Commun"},{"issue":"1","key":"3141_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58435-9","volume":"16","author":"D Bian","year":"2025","unstructured":"Bian D, Ji S, Liu Y, et al. Neoadjuvant aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial. Nat Commun. 2025;16(1):3143. https:\/\/doi.org\/10.1038\/s41467-025-58435-9.","journal-title":"Nat Commun"},{"issue":"1","key":"3141_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ijrobp.2023.03.042","volume":"117","author":"N Peled","year":"2023","unstructured":"Peled N, Roisman LC, Levison E, et al. Neoadjuvant osimertinib followed by sequential definitive radiation therapy and\/or surgery in stage III epidermal growth factor receptor-mutant non-small cell lung cancer: an open-label, single-arm, phase 2 study. Int J Radiat Oncol Biol Phys. 2023;117(1):105\u201314. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.03.042.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"26","key":"3141_CR38","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1200\/JCO.24.00071","volume":"42","author":"CM Blakely","year":"2024","unstructured":"Blakely CM, Urisman A, Gubens MA, et al. Neoadjuvant osimertinib for the treatment of stage I-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer: a phase II multicenter study. J Clin Oncol. 2024;42(26):3105\u201314. https:\/\/doi.org\/10.1200\/JCO.24.00071.","journal-title":"J Clin Oncol"},{"key":"3141_CR39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.lungcan.2023.02.011","volume":"178","author":"C Lv","year":"2023","unstructured":"Lv C, Fang W, Wu N, et al. Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): a multicenter, single-arm, open-label phase 2b trial. Lung Cancer. 2023;178:151\u20136. https:\/\/doi.org\/10.1016\/j.lungcan.2023.02.011.","journal-title":"Lung Cancer"},{"issue":"10","key":"3141_CR40","doi-asserted-by":"publisher","first-page":"S609","DOI":"10.1016\/j.jtho.2019.08.1281","volume":"14","author":"A Tan","year":"2019","unstructured":"Tan A, Chua KP, Takano A, et al. P1.17-07 neoadjuvant gefitinib in resectable early stage EGFR mutant non-small cell lung cancer (NSCLC): a window-of-opportunity study. J Thorac Oncol. 2019;14(10):S609\u201310. https:\/\/doi.org\/10.1016\/j.jtho.2019.08.1281.","journal-title":"J Thorac Oncol"},{"key":"3141_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5460","volume":"367","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Liu J, Cai X, et al. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. BMJ. 2019;l5460. https:\/\/doi.org\/10.1136\/bmj.l5460.","journal-title":"BMJ"},{"issue":"8","key":"3141_CR42","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(11)70184-X.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3141_CR43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","volume":"389","author":"M Tsuboi","year":"2023","unstructured":"Tsuboi M, Herbst RS, John T, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med. 2023;389(2):137\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2304594.","journal-title":"N Engl J Med"},{"issue":"6","key":"3141_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70211","volume":"6","author":"S Li","year":"2025","unstructured":"Li S, Xu C, Meng Y, et al. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy versus neoadjuvant chemotherapy in non-small cell lung cancer treatment: a mixed method meta-analysis based on global randomized controlled trials. MedComm. 2025;6(6):e70211. https:\/\/doi.org\/10.1002\/mco2.70211.","journal-title":"MedComm"},{"key":"3141_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1569864","volume":"16","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Lin Y, Chen S. Efficacy of neoadjuvant, adjuvant, and perioperative immunotherapy in non-small cell lung cancer across different PD-L1 expression levels: a systematic review and meta-analysis. Front Immunol. 2025;16:1569864. https:\/\/doi.org\/10.3389\/fimmu.2025.1569864.","journal-title":"Front Immunol"},{"key":"3141_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1273220","volume":"14","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Feng B, Chen J, You L. Efficacy, safety, and survival of neoadjuvant immunochemotherapy in operable non-small cell lung cancer: a systematic review and meta-analysis. Front Immunol. 2023;14:1273220. https:\/\/doi.org\/10.3389\/fimmu.2023.1273220.","journal-title":"Front Immunol"},{"key":"3141_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf190","author":"R Aburaki","year":"2025","unstructured":"Aburaki R, Fujiwara Y, Haketa S, Horita N. Immune checkpoint inhibitors as neoadjuvant therapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis. J Natl Cancer Inst. 2025. https:\/\/doi.org\/10.1093\/jnci\/djaf190.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"3141_CR48","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","volume":"10","author":"M Sorin","year":"2024","unstructured":"Sorin M, Prosty C, Ghaleb L, et al. Neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and meta-analysis. JAMA Oncol. 2024;10(5):621. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0057.","journal-title":"JAMA Oncol"},{"key":"3141_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107885","volume":"194","author":"M Izumi","year":"2024","unstructured":"Izumi M, Costa DB, Kobayashi SS. Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer. Lung Cancer. 2024;194:107885. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107885.","journal-title":"Lung Cancer"},{"key":"3141_CR50","doi-asserted-by":"publisher","unstructured":"Circulating tumor DNA as a predictive biomarker for clinical outcomes with margetuximab and pembrolizumab in pretreated HER2-positive gastric\/gastroesophageal adenocarcinoma. Oncology. 2023;(3704):176\u2013183. https:\/\/doi.org\/10.46883\/2023.25920992","DOI":"10.46883\/2023.25920992"},{"issue":"5","key":"3141_CR51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2017421118","volume":"118","author":"S Jin","year":"2021","unstructured":"Jin S, Zhu D, Shao F, et al. Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy. Proc Natl Acad Sci U S A. 2021;118(5):e2017421118. https:\/\/doi.org\/10.1073\/pnas.2017421118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"3141_CR52","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1634\/theoncologist.2019-0003","volume":"24","author":"A Nakao","year":"2019","unstructured":"Nakao A, Hiranuma O, Uchino J, et al. Osimertinib in elderly patients with epidermal growth factor receptor T790M-positive non-small-cell lung cancer who progressed during prior treatment: a phase II trial. Oncologist. 2019;24(5):593-e170. https:\/\/doi.org\/10.1634\/theoncologist.2019-0003.","journal-title":"Oncologist"},{"issue":"3","key":"3141_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030841","volume":"15","author":"G Gomatou","year":"2023","unstructured":"Gomatou G, Syrigos N, Kotteas E. Osimertinib resistance: molecular mechanisms and emerging treatment options. Cancers. 2023;15(3):841. https:\/\/doi.org\/10.3390\/cancers15030841.","journal-title":"Cancers"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-026-03141-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-026-03141-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-026-03141-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:01:55Z","timestamp":1776718915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13643-026-03141-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3141"],"URL":"https:\/\/doi.org\/10.1186\/s13643-026-03141-w","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"14 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}